PGxAI Vega

Feb 28, 2025

PGxAI, a Palo Alto, California-based provider of AI-powered pharmacogenetics solutions, has launched Vega, its latest AI model designed to help physicians and health systems tailor drug therapy based on individual genetic profiles. Vega covers more than 1,200 drugs and 350 genes, which the company claims is 70 times the scope of traditional pharmacogenetic panels, made possible by the company's foundational GenAI model. The new platform also builds on the company's previous model, Sirius, which focused on risk classification by identifying patients prone to adverse drug reactions. The new model also interprets clinical guidelines and instantly generates treatment recommendations.

PGxAI Vega

Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth

Seer Q1 Revenues Rise 35 Percent

Biodesix Q1 Revenues up 21 Percent as Firm Slashes Full-Year Guidance on Sales Restructuring

MantaBio Nabs $2.5M in Seed Funding to Develop Microbial Detection Platform for Biopharma

Socioeconomic Factors, Not Genetic Ancestry, Linked to All-Cause Mortality in Black Americans